Natera(US:NTRA)2026-02-26 22:32Financial Data and Key Metrics Changes - The company processed approximately 924,000 tests in Q4 2025, achieving a record growth of 56% in MRD clinical unit tests compared to Q4 2024 [6][10] - Revenue for the quarter reached around $666 million, representing a 40% increase year-over-year [6][7] - Gross margin improved to 66.9% in Q4, exceeding expectations and reflecting strong operational performance [6][11] - Cash flow generated in 2025 was over $107 million, with expectations for continued strong cash flow in 2026 [7][30] Business Line Data and Key Metrics Changes - The MRD product portfolio expanded significantly with the launch of the genome version of Signatera and the Latitude MRD test, contributing to strong growth in oncology [8][9] - The average selling price (ASP) for Signatera increased to approximately $1,225 in Q4, with cash collections accelerating [11][30] - The women's health segment saw robust performance, particularly with the Fetal Focus test, which achieved high sensitivity and specificity [15][16] Market Data and Key Metrics Changes - Over 50% of oncologists in the U.S. ordered a Signatera test in Q4, indicating strong adoption of MRD testing in clinical practice [10] - The company is seeing increased engagement from commercial payers, enhancing reimbursement opportunities for its tests [12][30] Company Strategy and Development Direction - The company plans to generate between $2.62 billion and $2.7 billion in revenues for 2026, with a focus on maintaining gross margins between 63% and 65% while investing in R&D [7][31] - Strategic investments in clinical trials and product launches are expected to drive future growth, particularly in oncology and women's health [8][36] - The company is pursuing broader Medicare reimbursement for Signatera, which could significantly enhance revenue potential [12][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory, citing strong performance in Q4 and a solid start to 2026 [6][7] - The company is focused on maintaining operational improvements and expects to continue narrowing operating losses while investing in growth [30][31] - Management highlighted the importance of generating clinical evidence to support product adoption and reimbursement [46][61] Other Important Information - The company completed the acquisition of Foresight Diagnostics, integrating phased variant technology to enhance MRD test sensitivity [27][28] - The Latitude MRD assay has shown promising clinical validation, with significant prognostic capabilities for colorectal cancer [24][25] Q&A Session Summary Question: Update on Signatera ASPs and Medicare changes - Management indicated that changes in ADLT rates and bundle rates roughly net each other out, with continued execution on reimbursement expected to drive ASP growth [38][39] Question: Signatera mix by indication and potential impact on ASPs - The majority of Signatera volume comes from CRC, but management anticipates that breast and lung cancer indications will gain traction, potentially impacting ASPs positively [41][42] Question: Growth expectations for Signatera and data catalysts - Management suggested using trailing four-quarter averages for modeling growth, with expectations for continued strong performance across various tumor types [45][50] Question: Marketing approach for Fetal Focus and market share - Management noted significant physician interest in Fetal Focus, with flexible ordering options contributing to market share gains [52][54] Question: Contribution from lymphoma and multiple myeloma volumes - Management acknowledged limited current contributions from these areas but sees potential for growth driven by the Foresight team and their data [74][75] Question: Approval and launch plans for Signatera in Japan - Management confirmed a strong sales team and distribution partnership in Japan, anticipating a positive impact on revenue once approval is secured [76][79]